Lb Pharmaceuticals (LBRX) Retained Earnings (2024 - 2026)

Lb Pharmaceuticals' Retained Earnings history runs 3 years deep, the most recent figure standing at -$148.6 million for Q1 2026.

• On a quarterly basis, Retained Earnings changed N/A year-over-year to -$148.6 million in Q1 2026; TTM through Mar 2026 was -$148.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$129.5 million, down 116791.89% from the prior year.
• Retained Earnings slipped to -$148.6 million in Q1 2026 per LBRX's latest filing, from -$129.5 million in the prior quarter.
• Across five years, Retained Earnings topped out at $111000.0 in Q4 2024 and bottomed at -$148.6 million in Q1 2026.
• The 3-year median for Retained Earnings is -$123.8 million (2025), against an average of -$99.0 million.
• Biggest YoY gain for Retained Earnings was 116791.89% in 2025; the steepest drop was 116791.89% in 2025.
• Year by year, Retained Earnings stood at $111000.0 in 2024, then tumbled by 116791.89% to -$129.5 million in 2025, then decreased by 14.72% to -$148.6 million in 2026.
• Per Business Quant, the three latest LBRX Retained Earnings figures stand at -$148.6 million (Q1 2026), -$129.5 million (Q4 2025), and -$118.1 million (Q3 2025).